Specialty Pharma Journal Specialty, Precision & Technology
Holzkirchen, 6 March 2017 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today presented data for its proposed biosimilar adalimumab (GP2017). The Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint demonstrating GP2017 has equivalent efficacy to the reference medicine, Humira®1. Results …
Tag Archives: AAD
March, 2017
October, 2015
-
21 October
Novartis Expands its Immuno-Oncology Pipeline through Acquisitions and Licensing Agreements
Basel, October 21, 2015 – Novartis announced today that it is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation. With four candidates currently in clinical trials and five more agents expected to enter the clinic by the end …
-
9 October
Boehringer Ingelheim’s Psoriasis Drug Demonstrates Positive Mid-Stage Results
Ingelheim, Germany, October 8, 2015 – New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066*, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in …